Search

Expert Perspectives Series – Usher Syndrome and Retinitis Pigmentosa

Webcast

… Expert Perspectives Series – Usher Syndrome and Retinitis Pigmentosa ProQR Expert Perspectives Series on …

June 22, 2020
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec.

December 16, 2021
Eye on the Future Forum - Spring Summit

Webcast

… latest clinical data for USH2A mediated Usher syndrome and retinitis pigmentosa and a live panel discussion. Check out the program …

April 15, 2021
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov.

November 21, 2019
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept.

September 09, 2019
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

December 11, 2019
ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug.

August 12, 2019
Fall Eye on the Future Forum (EFF) Summit 2020

Virtual Congress

The EFF is a growing multiple stakeholder platform for the exchange and sharing of insights and innovations to drive the future of clinical development in inherited retinal diseases. Organized by ProQR

September 23, 2020
ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a

Press release

Designation is for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene

January 30, 2020
ProQR update and additional sepofarsen Illuminate trial analyses

News update

ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.

April 13, 2022